Switch theme
Sign up to access all valuation multiples
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
2001
n/a
LTM Revenue n/a
LTM EBITDA n/a
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Brightgene Bio-medical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Brightgene Bio-medical achieved revenue of $177M and an EBITDA of $44.2M.
Brightgene Bio-medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Brightgene Bio-medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $163M | $177M | XXX | XXX | XXX |
| Gross Profit | $88.3M | $90.7M | XXX | XXX | XXX |
| Gross Margin | 54% | 51% | XXX | XXX | XXX |
| EBITDA | $42.9M | $44.2M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 25% | XXX | XXX | XXX |
| Net Profit | $33.0M | $27.9M | XXX | XXX | XXX |
| Net Margin | 20% | 16% | XXX | XXX | XXX |
| Net Debt | $71.7M | $107M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, Brightgene Bio-medical's stock price is CNY 39 (or $5).
Brightgene Bio-medical has current market cap of CNY 16.3B (or $2.2B), and EV of CNY 17.7B (or $2.4B).
See Brightgene Bio-medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, Brightgene Bio-medical has market cap of $2.2B and EV of $2.4B.
Brightgene Bio-medical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Brightgene Bio-medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Brightgene Bio-medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 13.8x | XXX | XXX | XXX |
| EV/EBITDA | 55.2x | XXX | XXX | XXX |
| P/E | 86.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1521.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBrightgene Bio-medical's NTM/LTM revenue growth is n/a
Brightgene Bio-medical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Brightgene Bio-medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Brightgene Bio-medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Brightgene Bio-medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 38% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Brightgene Bio-medical acquired XXX companies to date.
Last acquisition by Brightgene Bio-medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Brightgene Bio-medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Brightgene Bio-medical founded? | Brightgene Bio-medical was founded in 2001. |
| Where is Brightgene Bio-medical headquartered? | Brightgene Bio-medical is headquartered in China. |
| Is Brightgene Bio-medical publicy listed? | Yes, Brightgene Bio-medical is a public company listed on SHG. |
| What is the stock symbol of Brightgene Bio-medical? | Brightgene Bio-medical trades under 688166 ticker. |
| When did Brightgene Bio-medical go public? | Brightgene Bio-medical went public in 2019. |
| Who are competitors of Brightgene Bio-medical? | Similar companies to Brightgene Bio-medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Brightgene Bio-medical? | Brightgene Bio-medical's current market cap is $2.2B |
| What is the current revenue growth of Brightgene Bio-medical? | Brightgene Bio-medical revenue growth between 2023 and 2024 was 9%. |
| Is Brightgene Bio-medical profitable? | Yes, Brightgene Bio-medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
